Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Related Symbols 1

O OCGN OCGN

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #3,340

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Comments

User Menu